Dr. Robert G. Gish: January 28, 2019


Learn the Risk Factors and Importance of Seeking Care


Hepatologist, Adjunct Professor of Medicine at Stanford University

Patient who was treated for chronic HCV

3.4 million people are infected with chronic hepatitis C virus (HCV) in the United States. i Chronic HCV is a major cause of cirrhosis and liver cancer, and a primary reason for liver transplants. ii HCV infection has also been associated with depression, anxiety disorders, and renal disease as well as many other diseases and cancers. iii, iv, v, vi

For those who are diagnosed, many factors could lead a patient to refrain from seeking care. These may include stigma, not experiencing symptoms, lack of access to treatment or fear of side effects. vii, viii, ix

If you or a loved one has been diagnosed with HCV, it is important to seek care, even if you are not experiencing symptoms. HCV is a curable* disease, and effective treatments are available. x

On January 28, Dr. Robert G. Gish will be available for interviews. He will tell your listeners the statistics, risk factors and symptoms of HCV. He’ll be joined by Tim, a patient who was treated for chronic HCV.

*Cure means the hepatitis C virus is not detectable in the blood months after treatment ends. Individual results may vary.

For more information please visit: www.HepC.com  or call 1-844-HEPCINFO (844-437-2463)

More About Dr. Gish:

Dr. Gish obtained his medical degree from the University of Kansas Medical School. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish is a fellow of both the American College of Physicians and the American Association for the Study of Liver Disease. He is currently an Adjunct Professor of Medicine at Stanford University in Palo Alto and an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas and Reno and the Skaggs School of Pharmacy and Pharmaceutical Sciences in San Diego. In addition, he is also Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania.

For technical information, please contact: Deb Kehr at 917-572-3086

i Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1)(suppl):7787.

ii Centers for Disease Control and Prevention. Hepatitis C Questions and Answers for the Public. Available at https://www.cdc.gov/hepatitis/hcv/cfaq.htm Accessed November 26, 2018.

iii Monaco et al. HCV –related Nervous System Disorders. Clin Dev Immunol. 2012. doi: 10.1155/2012/236148.

iv Mathew S, Faheem M,Ibrahim SM, et al. Hepatitis C virus infection and neurological change. World J Hepatol. 2016;8(12):545-556.

v Park H, Adeyemi A, Henry L et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepatitis. 2015;22:897-905

vi Mahaleb P, Torres HA, Kramer JR, et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study. Cancer, 2017;123(7), 1202-1211. doi:10.1002/cncr.30559.

vii American Association for the Study of Liver Diseases. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at https://www.hcvguidelines.org/evaluate/testing-and-linkage. Updated May 24, 2018. Accessed November 26, 2018.

viii Kapadia, Shashi N et al. Strategies for Improving Hepatitis C Treatment Access in the United States:State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. J Public Health Manag Pract. 2018 Jun 20. doi: 10.1097/PHH.0000000000000829. [Epub ahead of print]

ix Treloar et al. Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social Perspective. Clinical Infectious Diseases. 2013; 57(2): S51-55

x World Health Organization:  Hepatitis C – Key Facts – July 2018. http://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

Speak Your Mind